2022 Pan Pacific Lymphoma Conference " Expert Insights

Target Audience
The 2022 Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. This enduring activity will benefit members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Discuss common strategies and treatments in the management of lymphoma involving infectious disease prophylaxis, situations for consideration of therapy dose reductions, transfusion pharmacotherapeutics, orphan drugs, and fertility preservation
Identify factors related to provider burnout and the impact of its circumstances on patients’ and providers’ well-being
Describe the molecular insights of lymphomagenesis and the pathological pathway to diagnosis of difficult cases
Discuss how minimal residual disease and imaging technologies can be incorporated to assist in improving treatment response evaluations
Assess novel and future therapies for the initial treatment of classical Hodgkin lymphoma (cHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), primary central nervous system (CNS) lymphoma, and peripheral T-cell lymphomas (PTCL)
Evaluate the diverse landscape of monoclonal gammopathies of significance and the intersection of plasma cell dyscrasias
Analyze clinical trial results concerning prognosis and transplant eligibility criteria for patients with relapsed cHL, FL, marginal zone lymphoma (MZL), and primary refractory DLBCL
Differentiate approaches to treatment for relapsed DLBCL between the need for autologous transplantation versus CAR-T therapy
Explain the roles of the interprofessional health care team in the diagnosis, treatment, management, and support of lymphoma and hematologic malignancies